In 2024, the number of ****** cancer cases among women in Japan reached approximately ******, which made it the most common type of cancer for women. The estimated total number of cancer cases for Japanese women in that year amounted to almost 421,000. Most common types of cancer in Japan Following breast cancer, colon and rectum, lung, as well as stomach were the most frequently diagnosed cancer sites among women in Japan. In contrast, prostate cancer was the most frequently diagnosed cancer among men, followed by stomach, colon and rectum, and lung cancer.Different types of cancer rank among the most common causes of death among Japanese people. In terms of cancer-related mortality among women in Japan, lung cancer claimed the highest number of lives in recent years, followed by pancreatic cancer.  Prevention and treatment of breast cancer In recent years, colon, cervix, lung, breast, and stomach were the most common cancer sites for screening in Japan. This was supported by a survey from 2023, in which over 36 percent of Japanese women stated that they had a cancer screening in the past two years.More attention has been given to breast cancer treatment as the incidence of breast cancer in Japan has grown throughout the past decades. Consequently, the number of general hospitals equipped with breast surgery departments increased as well.The early detection of breast cancer is crucial to increase the chance of survival. The primary approach to breast cancer treatment involves surgical removal of the cancer, though preoperative drug therapy may be administered based on the cancer's condition.

In 2024, the number of ******** cancer cases among Japanese men was estimated to be around 91.8 thousand. Following were **************** cancer, estimated to reach around 85.6 thousand cases, and **** cancer with around 85 thousand cases that year.

In 2024, the estimated number of cancer cases diagnosed in men amounted to around ***** thousand. The projected number of cancer cases of women was much lower in that year.

To investigate the global incidence of prostate cancer with special attention to the changing age structures. Data regarding the cancer incidence and population statistics were retrieved from the International Agency for Research on Cancer in World Health Organization. Eight developing and developed jurisdictions in Asia and the Western countries were selected for global comparison. Time series were constructed based on the cancer incidence rates from 1988 to 2007. The incidence rate of the population aged ≥ 65 was adjusted by the increasing proportion of elderly population, and was defined as the “aging-adjusted incidence rate”. Cancer incidence and population were then projected to 2030. The aging-adjusted incidence rates of prostate cancer in Asia (Hong Kong, Japan and China) and the developing Western countries (Costa Rica and Croatia) had increased progressively with time. In the developed Western countries (the United States, the United Kingdom and Sweden), we observed initial increases in the aging-adjusted incidence rates of prostate cancer, which then gradually plateaued and even decreased with time. Projections showed that the aging-adjusted incidence rates of prostate cancer in Asia and the developing Western countries were expected to increase in much larger extents than the developed Western countries.

In 2020, there was a breast cancer incidence of approximately ***** thousand among women in Japan. The number of cases increased significantly from over ** thousand in 2003.

Multi-Cancer Early Detection Tests Market Outlook

According to our latest research, the Global Multi-Cancer Early Detection Tests market size was valued at $2.1 billion in 2024 and is projected to reach $8.7 billion by 2033, expanding at a robust CAGR of 17.2% during the forecast period of 2025–2033. The primary growth catalyst for this market is the rising global burden of cancer, coupled with increasing awareness about the benefits of early detection and the rapid advancement of non-invasive diagnostic technologies. As cancer remains a leading cause of mortality worldwide, healthcare systems and patients are increasingly prioritizing early detection solutions that can identify multiple cancers from a single test, thereby improving survival rates and reducing healthcare costs. The integration of innovative technologies such as next-generation sequencing and liquid biopsy is significantly enhancing the accuracy and accessibility of these tests, further propelling market growth on a global scale.

Regional Outlook

North America currently dominates the Multi-Cancer Early Detection Tests market, accounting for the largest share of the global revenue. This leadership is primarily attributed to the region's mature healthcare infrastructure, high adoption rate of advanced diagnostic technologies, and favorable reimbursement policies. The United States, in particular, is at the forefront, with major investments in research and development, a robust presence of key industry players, and strong regulatory support from agencies such as the FDA. The region's proactive approach to cancer screening, coupled with widespread awareness campaigns and a growing emphasis on preventive healthcare, has resulted in early adoption and widespread utilization of multi-cancer early detection tests. Additionally, collaborations between academic institutions and biotech firms have accelerated innovation, further solidifying North America's position as the market leader.

The Asia Pacific region is projected to be the fastest-growing market for Multi-Cancer Early Detection Tests, with a forecasted CAGR exceeding 20% during 2025–2033. This exceptional growth is driven by a surge in healthcare investments, rising cancer incidence, and increasing government initiatives to improve early cancer diagnosis. Countries such as China, Japan, and India are witnessing a rapid expansion in healthcare infrastructure and a growing middle-class population with greater access to advanced medical technologies. Strategic partnerships with global players and the establishment of local manufacturing units are further enhancing market penetration. Moreover, the region's large and aging population base, combined with heightened awareness about the importance of early detection, is fueling demand for innovative, non-invasive diagnostic solutions.

In emerging economies across Latin America, the Middle East, and Africa, the adoption of Multi-Cancer Early Detection Tests is gradually gaining momentum, albeit at a slower pace due to several challenges. Limited healthcare infrastructure, budget constraints, and a lack of widespread awareness about the advantages of early detection pose significant barriers to market growth in these regions. However, ongoing policy reforms, increasing investments in public health, and growing collaborations with international organizations are expected to create new opportunities for market expansion. Localized demand is also being influenced by the rising prevalence of cancer and the need for cost-effective diagnostic solutions tailored to resource-constrained settings. As governments and non-profit organizations intensify their efforts to improve cancer outcomes, the market in these regions is poised for steady, albeit incremental, growth.

Report Scope

The Japanese digital X-ray market, a segment of the global market valued at $560.84 million in 2025 and exhibiting a Compound Annual Growth Rate (CAGR) of 9.54%, presents significant opportunities for growth. Driven by factors such as an aging population requiring increased diagnostic imaging, rising prevalence of chronic diseases like cancer and cardiovascular ailments necessitating frequent X-rays, and government initiatives promoting healthcare infrastructure modernization, the market is poised for expansion. Technological advancements, such as the adoption of direct radiography offering superior image quality and faster scan times compared to computed radiography, further fuel this growth. While the availability of advanced imaging technologies like MRI and CT scans may pose some restraint, the relative affordability and accessibility of digital X-ray systems, particularly portable units for remote areas and specialized applications, ensure sustained demand. Within Japan's market, the orthopedic and oncology segments are expected to be particularly robust, driven by high incidence rates of related diseases and a large aging population. Hospitals and diagnostic centers constitute the major end-users, though the increasing prevalence of mobile clinics and telemedicine may broaden the end-user segment in the coming years. Key players like Fujifilm Holdings Corporation, Canon Medical Systems Corporation, and Shimadzu Corporation, with their established presence and technological capabilities, will continue to dominate, while smaller players might focus on niche applications and regions. Growth within the Japanese market will largely depend on government healthcare spending, technological innovation focused on AI-powered image analysis for improved diagnostic accuracy and efficiency, and the expansion of medical tourism. Factors such as stringent regulatory approvals, potential price sensitivity among consumers, and the need for skilled personnel to operate and interpret X-ray images may pose challenges. However, the overall trajectory suggests a positive growth outlook for the foreseeable future. The market segmentation analysis reveals strong potential in portable systems for enhanced accessibility and direct radiography technology for improved efficiency and image quality. These factors, coupled with the projected growth rate, indicate a robust investment potential in this sector. Analyzing the regional performance within Japan could offer further opportunities for targeted investment strategies. Recent developments include: April 2023: Canon Inc., Canon Medical Systems Corporation (Canon Medical), and the National Cancer Center Japan (NCC) have begun clinical research employing a next-generation X-ray CT system with photon-counting computed tomography (photon-counting CT, PCCT)., June 2022: Konica Minolta, Inc. released DDRAtlas Ver. 1.0, which records normal cases, as the first part of Dynamic Digital Radiography DDRAtlas on its membership website in Japan. With the help of a DDR system that can record dynamic images utilizing a standard X-ray system, Konica Minolta has been attempting to provide new diagnostic values in Japan.. Key drivers for this market are: Increasing Prevalence of Chronic Diseases, Increasing Technological Advancements. Potential restraints include: Increasing Prevalence of Chronic Diseases, Increasing Technological Advancements. Notable trends are: Cancer Segment is Expected to Hold a Significant Market Share Over the Forecast Period.

Snapshot img

Precision Pathology For Cancer Market Size 2025-2029

The global precision pathology for cancer market is projected to see substantial growth, with an estimated market size and a CAGR of 8.2% during the forecast period. Access detailed market insights upon report purchase. The precision pathology for cancer market is being drives by the rising incidence of cancer and the subsequent demand for enhanced personalized therapies. Digital pathology, boosted by AI and machine learning, enhances diagnostic accuracy, accelerates diagnosis rates, and facilitates therapeutic recommendations, thereby significantly contributing to market expansion. Technological advancements, such as AI tools that improve diagnostic precision and treatment planning in cancer care, are also expected to fuel market growth. The increasing investments in research and development activities will further contribute to market expansion.

To access the full market forecast and comprehensive analysis, Buy Now

How is this market segmented?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in USD bn for the period 2025-2029, as well as historical data from 2019-2024 for the following segments:

Product

  Consumables
  Instruments


Technology

  Next-Generation Sequencing (NGS)
  Molecular Diagnostics
  Digital Pathology
  Artificial Intelligence (AI) and Machine Learning (ML)
  Liquid Biopsies
  Imaging Technologies


Applications

  Breast Cancer
  Lung Cancer
  Colorectal Cancers
  Prostate Cancer
  Melanoma And Non-Melanoma Skin Cancers


End-use

  Hospitals
  Diagnostic Laboratories
  Research Institutes


APAC

  China
  India
  Japan
  Australia
  Rest of APAC

Europe


  Germany
  Spain
  Italy
  UK
  Rest of Europe

North America


  US
  Canada

South America & MEA


  Brazil
  UAE
  South Africa
  Others





End-use

  Hospitals: Hospitals are key end-users, utilizing precision pathology for in-house diagnostics and treatment planning.
  Research Institutes: Research institutes use precision pathology for cancer research and development of new diagnostic and therapeutic strategies.
  Diagnostic Laboratories: Diagnostic laboratories provide precision pathology services to hospitals and other healthcare providers.


Product

  Consumables: This segment includes antibodies, kits & reagents, and probes used in precision pathology, driven by the increasing volume of diagnostic tests.
  Instruments: This segment encompasses slide staining systems, tissue processing systems, and PCR instruments, crucial for accurate pathological analysis.


Technology

  Liquid Biopsies: Liquid biopsies offer non-invasive methods for detecting cancer biomarkers, aiding in early diagnosis and treatment monitoring.
  Digital Pathology: Digital pathology solutions improve diagnostic accuracy and support therapeutic recommendations, enhancing overall efficiency.
  Imaging Technologies: Imaging technologies like CT, MRI, and ultrasound provide detailed anatomical and functional information for cancer diagnosis and treatment.
  Molecular Diagnostics: Molecular diagnostics are used to detect specific biomarkers and genetic mutations in cancer cells, facilitating targeted therapies.
  Next-Generation Sequencing (NGS): NGS technology is vital for genetic profiling of tumors, enabling personalized treatment strategies.
  Artificial Intelligence (AI) and Machine Learning (ML): AI and ML algorithms aid in analyzing complex pathological data, improving diagnostic precision and treatment planning.


Applications

  Lung Cancer: Genetic profiling helps in selecting appropriate treatments for different types of lung cancer.
  Breast Cancer: Precision pathology is critical in identifying specific subtypes of breast cancer, guiding targeted therapies.
  Prostate Cancer: Precision diagnostics help in determining the aggressiveness of prostate cancer and guiding treatment decisions.
  Colorectal Cancers: Precision pathology aids in identifying genetic mutations that influence treatment response in colorectal cancer.
  Melanoma And Non-Melanoma Skin Cancers: Molecular analysis assists in identifying specific mutations in skin cancers, enabling personalized therapies.

Regional Analysis

APAC: The Asia-Pacific (APAC) region is expected to experience rapid growth in the precision pathology for cancer market, driven by increasing healthcare expenditure, a rising prevalence of cancer, and growing awareness of precision medicine. China and India are key markets in APAC, with significant investments in healthcare infrastructure and a large patient pool, making them major hubs for precision pathology services.
Europe: Europe holds a substantial share of the precision pathology for cancer market, characterized by advanced healthcare systems, a strong focus on research and development, and a high adoption rate of advance

Population, aging rate, community SES indicators, cancer incidence, and death due to cancer in Kanagawa, Japan, 2000–2015.

Proton Therapy Systems Market Outlook

According to our latest research, the Global Proton Therapy Systems market size was valued at $2.1 billion in 2024 and is projected to reach $5.6 billion by 2033, expanding at a robust CAGR of 11.2% during the forecast period of 2024–2033. The primary growth driver for this market is the increasing global prevalence of cancer, coupled with rising demand for advanced, minimally invasive, and highly targeted radiation therapies. Proton therapy, with its precision in targeting tumors while sparing healthy tissues, is gaining traction as a preferred modality, especially for pediatric and complex cancers. This trend is being further fueled by technological advancements in proton therapy systems, growing awareness among healthcare professionals, and supportive policy frameworks that promote the adoption of cutting-edge cancer treatment technologies.

Regional Outlook

North America currently commands the largest share of the global proton therapy systems market, accounting for nearly 42% of total market revenue in 2024. The region’s dominance is attributed to its mature healthcare infrastructure, high adoption rates of advanced medical technologies, and substantial investments in cancer research and treatment facilities. The United States, in particular, leads the charge, with numerous state-of-the-art proton therapy centers and a supportive reimbursement landscape. Favorable government policies, a strong presence of leading medical device manufacturers, and robust funding for oncology research further bolster the market. Additionally, the region’s proactive approach to early cancer diagnosis and the increasing prevalence of cancer cases continue to drive demand for proton therapy systems, positioning North America as the epicenter of innovation and adoption in this sector.

The Asia Pacific region is forecasted to be the fastest-growing market for proton therapy systems, with a projected CAGR exceeding 14.5% during 2024–2033. This rapid growth is underpinned by rising cancer incidence rates across populous countries such as China, India, and Japan, coupled with expanding healthcare budgets and infrastructure development. Governments in the region are increasingly prioritizing cancer care, leading to significant investments in advanced treatment modalities like proton therapy. Japan has emerged as a regional leader, with notable government support and several operational proton therapy centers. Meanwhile, China is witnessing a surge in both public and private investments aimed at establishing new proton therapy facilities. The increasing awareness of the benefits of proton therapy, along with improvements in healthcare accessibility and insurance coverage, are key factors driving the market’s exponential growth in Asia Pacific.

Emerging economies in Latin America and the Middle East & Africa are gradually embracing proton therapy, though at a slower pace due to infrastructural and economic constraints. These regions face challenges such as limited access to capital-intensive medical equipment, insufficient trained personnel, and lack of specialized treatment centers. However, localized demand is steadily rising, particularly in urban centers where cancer prevalence is increasing and private healthcare providers are seeking to differentiate themselves through advanced treatment offerings. Policy reforms aimed at improving healthcare infrastructure, alongside international collaborations and technology transfer agreements, are beginning to facilitate the adoption of proton therapy systems. Despite these positive trends, the market’s growth in emerging economies remains contingent on overcoming barriers related to funding, regulatory approvals, and the establishment of sustainable operational models.

Report Scope

The Asia-Pacific cancer vaccines market is experiencing robust growth, projected to reach $2.34 billion in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 11.55% from 2025 to 2033. This expansion is driven by several key factors. Rising cancer incidence rates across the region, particularly in rapidly developing economies like China and India, fuel the demand for effective preventative and therapeutic vaccines. Furthermore, increasing government initiatives focused on improving healthcare infrastructure and raising public awareness about cancer prevention contribute significantly to market growth. Technological advancements in vaccine development, including the emergence of more targeted and personalized therapies like recombinant and viral vector vaccines, are also major contributors. The market is segmented by technology (recombinant, whole-cell, viral vector/DNA, and others), treatment method (preventive and therapeutic), application (prostate, cervical, and other cancers), and geography (China, Japan, India, Australia, South Korea, and the Rest of Asia-Pacific). China and India are expected to be the largest markets within the region due to their substantial populations and expanding healthcare sectors. While the market displays strong growth potential, challenges remain. High research and development costs associated with bringing new cancer vaccines to market, coupled with stringent regulatory approvals, present hurdles for companies. Furthermore, ensuring equitable access to these life-saving vaccines across varying socioeconomic strata within the diverse Asia-Pacific region poses a significant challenge. Despite these restraints, the long-term outlook for the Asia-Pacific cancer vaccines market remains positive, fueled by continuous innovation, growing healthcare expenditure, and a rising understanding of the importance of cancer prevention and treatment. The market’s future trajectory hinges on successful clinical trials, favorable regulatory outcomes, and effective strategies to improve vaccine affordability and accessibility across the diverse populations of the region. Recent developments include: January 2023: Genexine, a publicly traded, clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, received Fast Track Designation (FTD) from the Korean Ministry of Food and Drug Safety (MFDS) for GX-188E (tirvalimogene teraplasmid), its first-in-class proprietary therapeutic DNA vaccine. GX-188E has the potential to be a key life-saving drug for the treatment of advanced cervical cancer., September 2022: The Central government of India launched the Indian vaccine against cervical cancer Quadrivalent Human Papillomavirus vaccine (HPV). This vaccine was developed by the Serum Institute of India (SII) and the Department of Biotechnology (DBT).. Key drivers for this market are: Growing Burden of Cancer, Emphasis on Early Diagnosis of Cancer; Technological Developments in Cancer Vaccines. Potential restraints include: Growing Burden of Cancer, Emphasis on Early Diagnosis of Cancer; Technological Developments in Cancer Vaccines. Notable trends are: Preventive Vaccines is Expected to Show Better Growth Over the Forecast Period..

DNA Methylation Cancer Atlas Panels Market Outlook

According to our latest research, the Global DNA Methylation Cancer Atlas Panels market size was valued at $412 million in 2024 and is projected to reach $1.08 billion by 2033, expanding at a CAGR of 11.3% during 2024–2033. The primary growth driver for this market is the increasing prevalence of cancer worldwide, which is compelling healthcare providers and researchers to adopt advanced epigenetic profiling tools for early diagnosis, prognosis, and personalized treatment strategies. As cancer detection and management move toward precision medicine, the demand for comprehensive methylation panels that enable high-throughput, accurate, and cost-effective analysis of cancer-specific biomarkers is accelerating rapidly. This surge is further amplified by ongoing technological innovations in sequencing and PCR-based platforms, which are continuously improving the sensitivity, specificity, and scalability of DNA methylation analysis.

Regional Outlook

North America currently dominates the DNA Methylation Cancer Atlas Panels market, accounting for the largest share of global revenues, estimated at over 42% in 2024. This leadership is attributed to the region's mature healthcare infrastructure, robust investment in cancer research, and the presence of leading biotechnology companies and academic institutions. The United States, in particular, benefits from favorable reimbursement policies, a high adoption rate of advanced diagnostics, and strong collaboration between public and private sectors. Additionally, the region’s proactive regulatory environment and ongoing government initiatives to advance precision medicine have fostered rapid commercialization of innovative methylation panels. The availability of skilled professionals and high awareness among clinicians and patients further solidify North America's position as the primary hub for DNA methylation-based cancer diagnostics and research.

Asia Pacific is emerging as the fastest-growing region in the DNA Methylation Cancer Atlas Panels market, forecasted to register a remarkable CAGR of 14.2% from 2024 to 2033. The surge in regional demand is driven by increasing cancer incidence rates in populous countries such as China, India, and Japan, coupled with rising healthcare expenditures and government initiatives to modernize diagnostic infrastructure. Significant investments in biomedical research, expanding collaborations with global players, and growing awareness about the benefits of early cancer detection are further propelling market growth in Asia Pacific. Local companies are also actively developing cost-effective and scalable methylation panels tailored to the unique genetic backgrounds of Asian populations, which is fostering broader adoption and market penetration across the region.

In emerging economies across Latin America, the Middle East, and Africa, the adoption of DNA Methylation Cancer Atlas Panels is gaining momentum, albeit at a slower pace compared to developed regions. These markets face unique challenges including limited access to advanced diagnostic technologies, lower healthcare spending, and inadequate reimbursement frameworks. However, increasing public and private sector investments in oncology research, growing partnerships with international diagnostic companies, and a gradual shift toward personalized medicine are creating new opportunities for market expansion. Policy reforms aimed at improving cancer care and the establishment of regional cancer registries are expected to drive incremental demand, although infrastructural constraints and affordability issues remain significant barriers to widespread adoption.

Report Scope

The present study assessed the incidence of drug-induced interstitial lung disease (ILD) recurrence among breast cancer patients who underwent rechallenge with cancer-directed therapy. Japanese insurance claims data and the Diagnosis Procedure Combination database (2009–2022) involving 81,601 patients were analyzed to evaluate 1,042 breast cancer patients who developed ILD. Of these, 566 patients underwent cancer-directed therapy rechallenge, and 42.1% of them were re-challenged with the same therapeutic regimen that caused the initial ILD. ILD recurrence was observed in 18.9% of the patients, with a median recurrence time of 40 days. The drugs most commonly causing ILD were cytotoxic agents, and those most frequently used for rechallenge were cytotoxic agents. A notable ILD recurrence rate was observed in breast cancer patients after a cancer-directed therapy rechallenge, highlighting the need for cautious treatment planning and personalised strategies to balance cancer control while mitigating ILD risk. This article discusses a study that researched a lung condition known as interstitial lung disease (ILD) in individuals with breast cancer who were treated again with cancer-directed therapy after recovering from ILD. ILD involves inflammation and damage to the lungs and can be a serious side effect of cancer treatment. We analyzed data from Japanese health insurance claims and hospital records from 2009 to 2022, of 81,601 patients with breast cancer, 1,042 developed ILD that required treatment with steroids. Of the 1,042 patients, 566 underwent cancer-directed therapy again after their initial ILD episode. The findings showed that approximately 19% of these patients experienced ILD recurrence, typically approximately 40 days after they had started cancer-directed therapy again. The most common rechallenge therapy for these patients was cytotoxic drugs, which are powerful and used to kill cancer cells. The results of this study highlight the risk of ILD recurrence in patients with breast cancer who undergo cancer-directed therapy again. This insight is crucial for doctors and patients when deciding on cancer treatments, especially after a patient has already had ILD. This demonstrates the importance of careful planning and personalized treatment strategies to manage the risk of ILD while attempting to effectively control cancer. This study helps in understanding the trade-off between treating cancer to protect patients while not causing serious side effects such as ILD.

The Japan nuclear imaging devices market, valued at $325.42 million in 2025, is projected to experience steady growth, driven by a rising geriatric population necessitating increased diagnostic procedures and technological advancements leading to improved image quality and faster scan times. The market's Compound Annual Growth Rate (CAGR) of 4.55% from 2025 to 2033 indicates a consistent expansion. Growth is fueled by the increasing prevalence of cardiovascular diseases, cancer, and neurological disorders, all of which benefit significantly from accurate and timely nuclear imaging diagnostics. Furthermore, government initiatives promoting healthcare infrastructure development and increased investment in advanced medical technologies are contributing factors. The segments within the market – equipment (SPECT and PET scanners, radioisotope production facilities) and radioisotopes (Technetium-99m, Fluorine-18, etc.) – are expected to witness parallel expansion, with PET radioisotopes potentially experiencing faster growth due to the rising demand for oncology diagnostics. Competition among established players like GE Healthcare, Siemens Healthineers, and Fujifilm, coupled with the emergence of innovative technologies, will shape market dynamics in the coming years. While potential restraints could include regulatory hurdles and cost considerations related to advanced equipment and radioisotopes, the overall market outlook remains positive due to the aforementioned growth drivers. The market segmentation further highlights the significant roles of specific applications. SPECT applications, predominantly in cardiology and orthopedics, maintain a substantial share, reflecting the continued importance of these procedures. However, PET applications, particularly in oncology, are poised for accelerated growth due to increasing cancer incidence rates and the superior diagnostic capabilities of PET scans in detecting and staging various types of cancers. The presence of key players like ATOX Co. Ltd, Bracco Imaging, and Canon indicates a competitive landscape characterized by continuous innovation and a focus on meeting evolving clinical needs. The market's trajectory suggests a robust future, especially with the continued technological advancements and increasing healthcare expenditure in Japan. Recent developments include: Oct 2022: The IAEA redesignated National Institutes for Quantum Science and Technology (QST) as a Collaborating Centre until 2026 for radiation oncology, nuclear medicine and molecular imaging, dosimetry, and science technology and society., Aug 2022: PeptiDream Inc., a Japan-based biopharmaceutical company, expanded its strategic partnership with RayzeBio Inc. to discover and develop peptide-radioisotope (RI) conjugates for use as radiopharmaceutical therapeutics. Under the terms of the agreement, RayzeBio grants PeptiDream an option to attain development and commercialization rights in Japan for the joint peptide-RI programs., Jan 2021: Fuzionaire Radioisotope Technologies K.K. entered into a feasibility study agreement with Nihon Medi-Physics Co. Ltd, a Japan-based radiopharmaceutical company, to develop and commercialize Fuzionaire Dx's radiopharmaceutical technologies in Japan.. Key drivers for this market are: Rise in Prevalence of Cancer and Cardiac Disorders, Increase in Technological Advancements; Growth in the Applications of Nuclear Medicine and Imaging. Potential restraints include: Rise in Prevalence of Cancer and Cardiac Disorders, Increase in Technological Advancements; Growth in the Applications of Nuclear Medicine and Imaging. Notable trends are: Oncology Segment is Expected to Witness Significant Growth Over the Forecast Period.

Snapshot img

Cancer Registry Software Market Size 2025-2029

The cancer registry software market size is valued to increase USD 121.9 million, at a CAGR of 14% from 2024 to 2029. The growing prevalence of cancer cases will drive the cancer registry software market.

Major Market Trends & Insights

North America dominated the market and accounted for a 51% growth during the forecast period.
By End-user - Government and third party segment was valued at USD 24.20 million in 2023
By Type - Stand-alone software segment accounted for the largest market revenue share in 2023

Market Size & Forecast

Market Opportunities: 181.04 million
Market Future Opportunities: USD 121.90 million
CAGR : 14%
North America: Largest market in 2023

Market Summary

The market encompasses a continually evolving landscape shaped by advancements in core technologies and applications, service types, and regulatory frameworks. With the growing prevalence of cancer cases worldwide, the demand for robust and efficient cancer registry software solutions has surged. The growth is fueled by the increasing clinical research for oncology and the need for accurate, standardized data collection and analysis.
However, data privacy and security concerns pose significant challenges, necessitating stringent compliance with regulations such as HIPAA and GDPR. As regional healthcare systems adopt digital transformation, the market is witnessing a proliferation of solutions tailored to specific needs in North America, Europe, and Asia Pacific.

What will be the Size of the Cancer Registry Software Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Cancer Registry Software Market Segmented and what are the key trends of market segmentation?

The cancer registry software industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

End-user

  Government and third party
  Pharma biotech and medical device companies
  Hospitals and medical practice
  Private payers
  Research institutes


Type

  Stand-alone software
  Integrated software


Deployment

  On-premises
  Cloud-based


Geography

  North America

    US
    Canada
    Mexico


  Europe

    France
    Germany
    Italy
    Spain
    UK


  APAC

    China
    Japan


  Rest of World (ROW)

By End-user Insights

The government and third party segment is estimated to witness significant growth during the forecast period.

Cancer registry software plays a pivotal role in assisting government and third-party agencies in managing and analyzing data related to cancer cases. These solutions facilitate the collection, storage, and statistical modeling of oncology data, enabling agencies to monitor cancer incidence, prevalence, and mortality rates. This information is essential for public health planning, resource allocation, and policy development. Governments utilize cancer registry software to ensure data quality through data validation rules, de-identification, and HIPAA compliance. They also employ data visualization tools, reporting dashboards, and data integration methods to analyze trends and patterns. This data analysis helps identify high-risk populations, geographic disparities, and emerging cancer types.

Moreover, cancer registry software supports population health management and patient data management, ensuring secure data storage, user access control, and audit trails. API integrations enable seamless data exchange with other healthcare systems, facilitating clinical data exchange and follow-up procedures. The future of cancer registry software is promising, with adoption expected to grow significantly. According to recent studies, the number of cancer registries worldwide is projected to increase by 20%, while the use of electronic registries is anticipated to surge by 30%. These trends reflect the ongoing digitization of healthcare and the growing recognition of the value of data-driven insights in improving cancer care and outcomes.

Request Free Sample

The Government and third party segment was valued at USD 24.20 million in 2019 and showed a gradual increase during the forecast period.

Furthermore, cancer registry software supports cancer surveillance, disease registries, and cancer staging, providing valuable data for mortality reporting and treatment protocols. It also facilitates incidence reporting, case ascertainment, and survival analysis, ensuring that governments and third-party agencies have access to the most accurate and up-to-date information for informed decision-making. In conclusion, cancer registry software is a crucial tool for governments and third-party agencies seeking to monitor and improve cancer care. Its features, including

Owing to the increasing number of elderly “baby boomers” in Japan, the number of cancer patients is also expected to increase. Approximately 2 million baby boomers from nearby local areas are residing in metropolitan areas; hence, the geographical distribution of cancer patients will probably markedly change. We assessed the expected number of breast cancer (BC) patients in different regions (urban, outer city, town, rural) using estimates of the nation’s population and Kanagawa Cancer Registry data. To estimate future BC incidence for each region, we multiplied the 2010 rate by the predicted female population for each region according to age group. The incidence cases of BC in those aged ≥65 years is expected to increase in all areas; in particular, compared to rates in 2010, the BC incidence in urban areas was predicted to increase by 82.6% in 2035 and 102.2% in 2040. Although the incidence in all BC cases in urban areas showed an increasing trend, until peaking in 2040 (increasing 31.2% from 2010), the number of BC patients would continue to decrease in other areas. The number of BC patients per capita BC specialist was 64.3 patients in 2010; this value would increase from 59.3 in 2010 to 77.7 in 2040 in urban areas, but would decrease in other areas. Our findings suggest that the number of elderly BC patients is expected to increase rapidly in urban areas and that the demand for BC treatment would increase in the elderly population in urban areas.

The Japan biliary tract cancers (BTCs) treatment market will reach USD 53.2 million in 2025 and is expected to grow at a steady year-on-year rate of 8.6% in total value during the forecast period, reaching USD 121.9 million by 2035.

Directional Brachytherapy Seed Market Outlook

According to our latest research, the Global Directional Brachytherapy Seed market size was valued at $512 million in 2024 and is projected to reach $1.02 billion by 2033, expanding at a CAGR of 8.1% during the forecast period 2025–2033. The primary factor propelling the growth of the Directional Brachytherapy Seed market globally is the increasing incidence of various cancers, particularly prostate, breast, and head and neck cancers, which has driven the demand for advanced, localized, and minimally invasive treatment modalities. The precision, efficacy, and reduced side effects associated with directional brachytherapy seeds are making them the preferred choice among oncologists and patients, further fueling market expansion. Additionally, ongoing technological advancements in seed design, improved imaging techniques, and growing awareness about early cancer diagnosis are contributing significantly to the robust growth trajectory of this market.

Regional Outlook

North America currently dominates the Directional Brachytherapy Seed market, accounting for the largest share of global revenue, with an estimated market value of $210 million in 2024. The region’s leadership is attributed to its mature healthcare infrastructure, high adoption rates of advanced cancer therapies, and strong presence of leading market players. Favorable reimbursement policies, robust research initiatives, and a high prevalence of cancer cases, particularly prostate and breast cancers, have further cemented North America’s position at the forefront of this market. The United States, in particular, is a key contributor, benefiting from significant investments in oncology research, widespread access to innovative medical technologies, and an established network of specialized cancer treatment centers. These factors collectively support the sustained growth and technological advancement of the market in this region.

The Asia Pacific region is projected to be the fastest-growing market for Directional Brachytherapy Seeds, with an impressive CAGR of 10.5% during the forecast period. This rapid growth is fueled by increasing healthcare investments, rising cancer incidence rates, and expanding access to advanced medical treatments across countries such as China, India, and Japan. Governments in the region are actively implementing initiatives to improve cancer screening and early diagnosis, which, in turn, is driving the adoption of brachytherapy. Additionally, the influx of international players, partnerships with local healthcare providers, and growing awareness about the benefits of minimally invasive cancer treatments are accelerating market penetration. As a result, Asia Pacific is poised to significantly enhance its share in the global market over the coming years.

In emerging economies across Latin America, the Middle East, and Africa, the Directional Brachytherapy Seed market is witnessing gradual adoption, albeit at a slower pace compared to developed regions. Key challenges include limited healthcare infrastructure, insufficient funding for cancer care, and a shortage of skilled oncologists and radiologists. However, localized demand is gradually rising due to increasing cancer awareness campaigns, non-governmental organization (NGO) involvement, and governmental efforts to upgrade cancer treatment facilities. Policy reforms aimed at expanding healthcare access and integrating advanced cancer therapies into public health systems are expected to create new growth opportunities. Nevertheless, these regions must overcome barriers related to affordability, regulatory approvals, and patient education to fully realize the market’s potential.

Report Scope

The Asia-Pacific liver cancer market, currently exhibiting robust growth, is projected to maintain a significant expansion trajectory throughout the forecast period (2025-2033). A compound annual growth rate (CAGR) of 5.20% indicates a substantial increase in market value, driven primarily by rising prevalence of liver cancer, particularly hepatocellular carcinoma (HCC), in the region. Increased awareness, improved diagnostic techniques (including ultrasound scans, CT scans, and biopsies), and advancements in targeted therapies, immunotherapy, and radiation oncology are major contributors to market growth. The rising geriatric population within the Asia-Pacific region, coupled with increasing lifestyle-related factors like alcohol consumption, hepatitis B and C infections, and non-alcoholic fatty liver disease (NAFLD), are fueling this demand. While a lack of healthcare infrastructure in certain areas poses a challenge, the increasing investment in healthcare infrastructure and the entry of major pharmaceutical companies with advanced treatment options are mitigating this restraint. The market is segmented by cancer type (primary and secondary liver cancers), treatment type (diagnostic and therapeutic procedures), and end-user (hospitals and other healthcare providers). China, Japan, India, and South Korea represent significant market segments, driven by their large populations and high incidence rates of liver cancer. The market's future growth is expected to be further influenced by the development and adoption of innovative treatment modalities, government initiatives to improve healthcare access, and increased investment in research and development of novel therapies. The segment encompassing therapeutic interventions, specifically targeted therapy and immunotherapy, is anticipated to demonstrate substantial growth owing to their improved efficacy and reduced side effects compared to conventional chemotherapy. Diagnostic procedures, particularly advanced imaging techniques, are also playing a crucial role, enabling earlier and more accurate diagnoses, thereby contributing to improved patient outcomes and driving market expansion. The competitive landscape is characterized by the presence of numerous established pharmaceutical and medical device companies, actively involved in developing and commercializing innovative treatment and diagnostic solutions. Their strategic collaborations, clinical trials, and investments in R&D are expected to further fuel the growth of the Asia-Pacific liver cancer market in the coming years. Growth will be particularly pronounced in emerging economies within the region, where healthcare infrastructure is rapidly improving and patient awareness is increasing. Recent developments include: In January 2022, Merck received conditional liver cancer treatment approval for its drug Keytruda based on its second confirmatory study., In January 2022, the LAUNCH trial conducted in China supported a potential new first-line treatment option for selected patients with advanced hepatocellular carcinoma (HCC).. Key drivers for this market are: Rising Burden of Liver Cancer, Increasing R&D Investments for the Development of Novel Therapies; Government Initiatives to Increase Cancer Awareness. Potential restraints include: Rising Burden of Liver Cancer, Increasing R&D Investments for the Development of Novel Therapies; Government Initiatives to Increase Cancer Awareness. Notable trends are: Hepatocellular Carcinoma Segment is Expected to Witness Significant Growth over the Forecast Period.

The Asia-Pacific pancreatic cancer therapeutics and diagnostics market is experiencing robust growth, projected to reach a substantial market size driven by increasing prevalence of pancreatic cancer, advancements in diagnostics and therapeutics, and rising healthcare expenditure across the region. The market's 6.40% CAGR from 2019 to 2024 suggests a significant expansion, with this momentum expected to continue through 2033. Key drivers include an aging population, lifestyle changes contributing to increased incidence rates, and greater awareness of the disease. Significant advancements in targeted therapies, such as immunotherapy and precision medicine approaches, are transforming treatment paradigms and contributing to market expansion. The segment dominated by targeted therapies is further propelled by ongoing research and development in this area. While the market faces challenges like high treatment costs and limited access to advanced diagnostic tools in certain regions, particularly in some parts of the Rest of Asia-Pacific, the overall growth trajectory remains positive. The strong presence of major pharmaceutical and medical device companies in the region, coupled with increasing government initiatives to improve cancer care infrastructure, further contributes to this growth. Within the Asia-Pacific region, China, Japan, India, and South Korea represent significant market segments due to their large populations, relatively high cancer rates, and improving healthcare infrastructure. The segment analysis reveals that the combination of surgery, chemotherapy, radiation therapy, and targeted therapy dominates treatment approaches. Advanced diagnostics, including imaging, biopsy, and endoscopy, are playing a crucial role in early detection and accurate diagnosis, driving market growth in the diagnostic segment. Future growth will likely be influenced by the success of ongoing clinical trials for novel therapies, government regulations and reimbursement policies impacting the affordability and accessibility of treatments and diagnostics, and the continued evolution of minimally invasive surgical techniques. The competitive landscape is characterized by established global players and emerging regional companies, fostering innovation and driving competition in the market. Key drivers for this market are: , Increasing Incidence and Prevalence of Pancreatic Cancer; Rising Awareness and Concern about the Disease; Technological Advancements and Innovation of New Products. Potential restraints include: , Increasing Incidence and Prevalence of Pancreatic Cancer; Rising Awareness and Concern about the Disease; Technological Advancements and Innovation of New Products. Notable trends are: Radiotherapy is Expected to register a High CAGR.